Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma

Future Oncology

Volumn 12, Issue 23, 2016, Pages 2683-2688

  Aya, Francisco ^a,b   Gaba, Lydia ^a,b   Victoria, Iván ^a,b   Fernández Martínez, Aranzazu ^a,b   Tosca, Mónica ^a,b   Prat, Aleix ^a,b   Arance, Ana ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

advanced melanoma; anti PD 1; immune related adverse event; ipilimumab; sequence of immunotherapies

Indexed keywords

IPILIMUMAB; ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOPATHOLOGY; LIVER DISEASE; MALE; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; ANTAGONISTS AND INHIBITORS; CANCER STAGING; DISEASE EXACERBATION; MELANOMA; METASTASIS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PATHOLOGY; RETREATMENT; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CTLA-4 ANTIGEN; DISEASE PROGRESSION; FEMALE; HUMANS; IPILIMUMAB; MALE; MELANOMA; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGRAMMED CELL DEATH 1 RECEPTOR; RETREATMENT; TREATMENT OUTCOME;

EID: 84995389680     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon-2016-0037     Document Type: Article

References (22)

1. John L, Cowey CL. The rapid emergence of novel therapeutics in advanced malignant melanoma. Dermatol. Ther. (Heidelb.) 5(3), 151-169 (2015).
2. Naidoo J, Page DB, Li BT et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann. Oncol. 26(12), 2375-2391 (2015).
3. Schadendorf D, Hodi FS, Robert C et al. Pooled analysis of long-term survival data from Phase II and Phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 33(17), 1889-1894 (2015).
4. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372(4), 320-330 (2015).
5. Weber JS, D'Angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, Phase 3 trial. Lancet Oncol. 16(4), 375-384 (2015).
6. Ribas A, Puzanov I, Dummer R et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, Phase 2 trial. Lancet Oncol. 16(8), 908-918 (2015).
7. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1). Eur. J. Cancer 45(2), 228-247 (2009).
8. Institute NC. Common Terminology Criteria for Adverse Events (CTCAE) Version 4. 0. http://evs. nci. nih. gov
9. Parry RV, Chemnitz JM, Frauwirth KA et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 25(21), 9543-9553 (2005).
10. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl Acad. Sci. USA 107(9), 4275-4280 (2010).
11. Selby M, Engelhardt J, Lu L-S. Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models. J. Clin. Oncol. 31 (2013).
12. Hamid O, Robert C, Daud A et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369(2), 134-144 (2013).
13. Postow MA, Chesney J, Pavlick AC et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372(21), 2006-2017 (2015).
14. Larkin J HF, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373(13), 1270-1271 (2015).
15. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
16. Hodi FS, Gibney G, Sullivan R et al. eds. An open-label, randomized, Phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064). Presented at: European Cancer Congress (ECC). Vienna, Austria, 25-29 September 2015.
17. Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J. Clin. Oncol. 33(18), 2092-2099 (2015).
18. Liakou CI, Kamat A, Tang DN et al. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc. Natl Acad. Sci. USA 105(39), 14987-14992 (2008).
19. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Ann. Rev. Immunol. 26, 677-704 (2008).
20. Prithviraj P, McArthur G, Atkinson V et al. Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy. J. Immunother. Cancer 3(Suppl. 2), P126 (2015).
21. Prithviraj P, McArthur GA, Atkinson V. Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy. J. Clin. Oncol. 33(Suppl.), Abstract 9059 (2015).
22. Danlos FX, Pages C, Roux J et al. Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma. Melanoma Res. 25(2), 178-179 (2015).